Hepatitis B: Serology Panels, Vaccination Pathway & Chronic Antiviral Monitoring

Hepatitis B virus injures hepatocytes through cytopathic and immune-mediated mechanisms, producing necroinflammatory activity measurable as ALT/AST rise and, when cholestasis dominates, bilirubin escalation. The hallmark surface antigen HBsAg marks active viral carriage; clearance leads to anti-HBs sometimes detectable after resolved infection or vaccination. Chronic replication maintains covalently closed circular DNA in the nucleus, explaining why therapy often suppresses rather than eradicates—hence the emphasis on long-term chronic-phase antiviral monitoring.

Compared with hepatitis A’s fecal-oral spread, HBV survives in blood and sexual fluids, driving different vaccination pathway prioritisation and occupational safety rules. Unlike curable hepatitis C, spontaneous cure of chronic HBV is uncommon; goals shift to fibrosis regression, HCC risk reduction, and complication prevention.

HBeAg-positive chronic hepatitis often shows higher HBV DNA with active ALT; spontaneous HBe seroconversion may follow. An inactive carrier pattern can emerge with low DNA and normal ALT despite persistent HBsAg—still not “benign” because flare and reactivation occur with chemotherapy or steroids. Nurses charting oncology or transplant pathways should preemptively verify serology panels whenever immune suppression is planned.

• HBeAg-positive immune-active: elevated ALT + HBV DNA—treatment-eligible pending specialist thresholds.
• HBeAg-negative chronic: fluctuating HBV DNA during ALT flares—needs longitudinal serology surveillance.
• Clinical cirrhosis: prioritise complication screens even if HBV DNA is low—coordinate with hepatology bundles.

Prodromal symptoms mirror other viral hepatitides: fatigue, nausea, low-grade fever, and myalgia. Icteric patients develop dark urine, pale stool, and right upper quadrant tenderness; some present with immune-complex phenomena (urticaria—do not anchor on rashes alone). Immunosuppressed hosts may show minimal symptoms until bilirubin climbs—track liver function tests and vital signs when risk flags exist.

When to probe deeper

• Hepatic encephalopathy pattern: sleep inversion, constructural apraxia, asterixis.
• Hemodynamic instability with sepsis physiology—ascites infection or bleeding can coexist.
• Heavy alcohol co-use—overlaps alcoholic hepatitis but does not negate antiviral indications when chronic HBV persists.

Perinatal exposure, unprotected sexual contact, contaminated sharps, injecting drug equipment, and inadvertent mucosal splash in procedural areas drive acquisition. Healthcare exposure after blood product workflows is rare due to screening yet remains in incident reviews. Metabolic context—NAFLD and diabetes mellitus type 2—does not transmit HBV but influences fibrosis pacing once chronic infection is established.

• Household exposures: toothbrush, razor, unmanaged wound drainage—education plus vaccine catch-up.
• HIV risk overlap: concurrent screening reduces loss to follow-up.
• Travel from endemic zones: reinforces catch-up hepatitis B vaccination in primary-care handoffs.

Diagnosis hinges on HBV antigen–antibody relationships interpreted alongside quantitative HBV DNA PCR and fibrosis assessment (transient elastography or biopsy when mandated). Admitting diagnoses often arrive as “positive HBsAg” from screening—duplicate labels without panel context cause handover errors.

Always align specimen collection with laboratory requirements—mislabelled tubes delay serology triage. Pair hand hygiene with safe phlebotomy after isolation precautions review.

1. Detect — Screen per USPSTF high-risk categories; confirm positive HBsAg with reflex DNA and expert panel copy.
2. Stratify — Grade synthetic function (INR, bilirubin, albumin), mental status, renal indices, and portal hypertension stigmata.
3. Treat — Initiate antivirals per hepatology/ID when DNA/ALT/fibrosis thresholds met; never interrupt HIV-active agents without cover.
4. Surveil — Six- to twelve-month labs when stable on therapy; renal review on tenofovir products—especially with CKD.
5. Escalate — Any encephalopathy, variceal bleed, sudden ALT crash, or AKI with ascites—senior review and likely higher-dependency bed.

• Hepatitis C — confirm with HCV RNA; curative direct-acting courses differ from HBV suppression goals.
• Autoimmune hepatitis — autoantibodies + IgG pattern; steroids differ.
• Drug-induced liver injury — temporal link to new agents; still check HBV serology if unclear.
• Biliary obstruction — dilated ducts on imaging; abdominal pain plus cholestatic labs.

Acute supportive care

Most adults self-limit; provide antiemetics, cautious analgesia avoiding hepatotoxic overload, glucose checks, and fluid balance precision. Observe for coagulopathy—repeat INR more frequently when trending upward.

Chronic antiviral therapy

First-line oral nucleos(t)ides centre on potent agents with high barrier to resistance—commonly entecavir or tenofovir formulations per local formulary, pregnancy planning, and renal profile. Pegylated interferon is occasionally used in selected HBeAg-positive patients where finite therapy is desired—monitor neuropsychiatric and cytopenic effects in nursing observation charts.

Special populations

• Pregnancy: antiviral prophylaxis when maternal viral load exceeds protocol cut-offs; coordinate birth-dose vaccine ± HBIG.
• Immunosuppression: antiviral prophylaxis when latent HBV could reactivate—document start/stop dates.
• Coinfected HIV: maintain two-drug HBV activity where guidelines demand—pharmacy verification before switches.

• Medication teaching: explain once-daily oral adherence ties directly to resistance risk; link to pharmacy blister packing when health literacy is low.
• Renal monitoring: schedule creatinine/eGFR alongside HBV DNA every visit when tenofovir disoproxil is used; report new proteinuria.
• Infection control: reinforce PPE discipline during dressing changes for bleeding varices or wound leaks.
• Transitions: ensure portable serology summary and next specialist date—loss to follow-up drives late HCC presentation.

Bedside monitoring checklist

• NEWS or local early-warning score after each antiviral titration or paracentesis.
• Neurological checks when ammonia-altering therapy starts.
• Strict I&O if diuretics or AKI concerns.
• GI bleed precautions when platelets fall with splenomegaly.

• Progressive fibrosis to cirrhosis with ascites, varices, and encephalopathy.
• HCC development—surveillance ultrasound ± AFP cadence per MDT.
• HBV reactivation under chemotherapy or anti-CD20 therapy without prophylaxis.
• Acute-on-chronic liver failure precipitated by sepsis, alcohol, or drug interactions.

Universal infant schedules and risk-based adult catch-up form the vaccination pathway. Seroprotection is confirmed with anti-HBs titres in healthcare workers when policies require. Post-exposure protocols combine vaccine acceleration ± HBIG depending on source status and recipient immunity—document every timestamp for legal defensibility.

Early-phase chronic HBV treated to complete virologic suppression approaches age-matched survival when fibrosis is mild. Cirrhosis already present at diagnosis carries higher decompensation and HCC risk despite therapy—set realistic expectations with MDT input.

Language matters: “positive hepatitis screen” frightens patients—pair results with what each marker means and the next appointment date. For HIV-coinfected individuals, never adjust antiretrovirals at the bedside without verifying HBV coverage—call pharmacy before any held dose.

While awaiting senior review: secure IV access, send repeat LFTs/coags, treat hypoglycaemia, avoid sedatives where possible, and prepare blood products per massive transfusion policy if variceal bleeding dominates.

These NCLEX-style clinical judgment practice items focus on the nursing priorities for this condition — recognise cues, escalate red flags, take safe action and evaluate outcomes (NCSBN Clinical Judgment Measurement Model) — through Priority FIRST, SATA, deterioration trends, multi-patient triage, ordered response, matrix matching and a compact cloze on the topic of hepatitis-B recognition (acute vs chronic, serology panels), structured vaccination / post-exposure prophylaxis / nucleos(t)ide antiviral monitoring and the acute-liver-failure / HCC / perinatal-transmission red flags.